V171
Biological
Merck Sharp & Dohme Corporation
Total Payments
$328,529
Transactions
6
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $197,529 | 5 | 0 |
| 2018 | $131,000 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $328,529 | 6 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| RSV Incidence and Hospitalization Associated Disability in Adults | Merck Sharp & Dohme Corporation | $328,529 | 0 |
Top Doctors Receiving Payments for V171
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $328,529 | 6 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $328,529
Product Information
- Type Biological
- Total Payments $328,529
- Total Doctors 0
- Transactions 6
About V171
V171 is a biological associated with $328,529 in payments to 0 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2018 to 2020. In 2020, $197,529 was paid across 5 transactions to 0 doctors.
The most common payment nature for V171 is "Unspecified" ($328,529, 100.0% of total).
V171 is associated with 1 research study, including "RSV Incidence and Hospitalization Associated Disability in Adults" ($328,529).